DK2016102T3 - Kimære T-cellereceptorer og tilhørende materialer og fremgangsmåder til anvendelse - Google Patents

Kimære T-cellereceptorer og tilhørende materialer og fremgangsmåder til anvendelse

Info

Publication number
DK2016102T3
DK2016102T3 DK07797329.5T DK07797329T DK2016102T3 DK 2016102 T3 DK2016102 T3 DK 2016102T3 DK 07797329 T DK07797329 T DK 07797329T DK 2016102 T3 DK2016102 T3 DK 2016102T3
Authority
DK
Denmark
Prior art keywords
methods
tcr
chimeric
host
tcrs
Prior art date
Application number
DK07797329.5T
Other languages
English (en)
Inventor
Richard A Morgan
Cyrille J Cohen
Steven A Rosenberg
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38668547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2016102(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK2016102T3 publication Critical patent/DK2016102T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK07797329.5T 2006-05-03 2007-05-03 Kimære T-cellereceptorer og tilhørende materialer og fremgangsmåder til anvendelse DK2016102T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79685306P 2006-05-03 2006-05-03
PCT/US2007/068113 WO2007131092A2 (en) 2006-05-03 2007-05-03 Chimeric t cell receptors and related materials and methods of use

Publications (1)

Publication Number Publication Date
DK2016102T3 true DK2016102T3 (da) 2012-07-02

Family

ID=38668547

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07797329.5T DK2016102T3 (da) 2006-05-03 2007-05-03 Kimære T-cellereceptorer og tilhørende materialer og fremgangsmåder til anvendelse

Country Status (9)

Country Link
US (2) US20090304657A1 (da)
EP (1) EP2016102B1 (da)
AT (1) ATE550356T1 (da)
AU (1) AU2007248019B2 (da)
CA (1) CA2651174A1 (da)
DK (1) DK2016102T3 (da)
ES (1) ES2382777T3 (da)
PT (1) PT2016102E (da)
WO (1) WO2007131092A2 (da)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
DE102006041455B4 (de) * 2006-09-04 2011-07-28 Johannes-Gutenberg-Universität Mainz, 55122 Verfahren zur Herstellung einer einen stabilisierten funktionellen humanen Einzelketten-Antigen-erkennenden-TCR (scTCR) exprimierenden Zelllinie, damit hergestellt Zelllinie, stabilisierter TAA-spezifischer scTCR, deren Verwendungen und diese enthaltende pharmazeutische Zusammmensetzungen
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
US9809797B2 (en) * 2007-10-03 2017-11-07 National Institutes Of Health (Nih) U.S. Dept. Of Health And Human Services (Dhhs) Division Of Extramural Inventions And Technology Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression
EP2318434A1 (en) * 2008-07-31 2011-05-11 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Her2/neu specific t cell receptors
EP2186825A1 (en) * 2008-11-13 2010-05-19 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Human-derived T cell receptors
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
WO2010075417A1 (en) * 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
US8785601B2 (en) 2009-01-28 2014-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
WO2010126766A1 (en) 2009-04-30 2010-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
GB0917094D0 (en) * 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9345748B2 (en) 2010-09-21 2016-05-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-SSX-2 T cell receptors and related materials and methods of use
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
RS61455B1 (sr) 2011-10-28 2021-03-31 Regeneron Pharma Genetski modifikovani miševi t ćelijskog receptora
CN104395344B (zh) 2012-05-07 2019-08-13 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
ES2835200T3 (es) 2012-05-22 2021-06-22 Us Health Uso médico de células que comprenden receptores de células T anti-NY-ESO-1
NZ741124A (en) * 2012-07-27 2019-11-29 Univ Illinois Engineering t-cell receptors
US10316289B2 (en) 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
SI2932264T1 (sl) 2012-12-14 2019-05-31 Biontech Rna Pharmaceuticals Gmbh Novi MHC-neodvisni, s tumorjem povezani antigeni
WO2014124280A1 (en) 2013-02-08 2014-08-14 Institute For Myeloma & Bone Cancer Research Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
US9486475B2 (en) 2013-02-08 2016-11-08 Amgen Research (Munich) Gmbh PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
JO3529B1 (ar) 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
SI2958937T1 (sl) 2013-02-22 2018-12-31 Regeneron Pharmaceuticals, Inc. Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks
DK2971045T3 (da) * 2013-03-13 2019-09-16 Health Research Inc Sammensætninger og fremgangsmåder til anvendelse af rekombinante T-celle-receptorer til direkte genkendelse af tumorantigen
AU2014235968B2 (en) 2013-03-21 2018-05-24 Ospedale San Raffaele Srl Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
CN110511960B (zh) * 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
GB201313377D0 (en) * 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
EP3083674B1 (en) 2013-12-19 2018-10-03 Friedrich-Alexander-Universität Erlangen-Nürnberg Influenza-specific t-cell receptor and its uses in the detection, prevention and/or treatment of influenza
EP3137100B1 (en) * 2014-04-15 2023-12-20 University Of Virginia Patent Foundation Isolated t cell receptors and methods of use therefor
PT3149031T (pt) * 2014-05-29 2020-03-25 Us Health Receptores de células t anti-e7 do papilomavírus humano 16
SI3149480T1 (sl) 2014-05-30 2019-05-31 Amgen Research (Munich) Gmbh Stratifikacija tveganj pri bolnikih z akutno limfoblastno levkemijo prekurzorjev b
KR102546296B1 (ko) * 2014-10-31 2023-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
SG10201913978RA (en) * 2014-11-26 2020-03-30 The United States Of America As Represented By The Secretary Anti-mutated kras t cell receptors
MX2017012829A (es) 2015-04-06 2018-02-23 Regeneron Pharma Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos.
AU2016273213B2 (en) 2015-06-01 2019-03-14 Medigene Immunotherapies Gmbh T cell receptor library
WO2016193300A1 (en) * 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh Method for generating antibodies against t cell receptor
KR101794304B1 (ko) * 2015-09-01 2017-11-06 가톨릭대학교 산학협력단 Ｅｂｖ 항원 특이 ｔ―세포 수용체 및 이의 용도
KR20180043800A (ko) * 2015-09-09 2018-04-30 이뮨 디자인 코포레이션 Ny-eso-1 특이적 tcrs 및 그의 사용 방법
WO2017070042A1 (en) 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
CN106632660B (zh) * 2015-11-04 2021-01-29 广东香雪精准医疗技术有限公司 识别ny-eso-1抗原短肽的tcr
TWI752930B (zh) 2015-12-23 2022-01-21 德商梅迪基因免疫治療公司 抗原特異性ｔｃｒ的新生成
DK3402515T3 (da) 2016-01-12 2021-11-15 Oncotracker Inc Forbedrede fremgangsmåder til monitorering af et individs immunstatus
DK3448882T3 (da) 2016-04-26 2022-02-21 Us Health Anti-kk-lc-1-t-cellereceptorer
JP7599819B2 (ja) 2016-06-02 2024-12-16 イムノコア リミテッド ｇｐ１００特異的ＴＣＲ－抗ＣＤ３ ｓｃＦｖ融合タンパク質の投薬レジメン
WO2018148454A1 (en) * 2017-02-09 2018-08-16 The Regents Of The University Of California Chimeric t cell antigen receptors and methods of use thereof
WO2018200582A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Chimeric antibody/t-cell receptor constructs and uses thereof
EP3622074A4 (en) 2017-05-12 2021-01-13 Augusta University Research Institute, Inc. HUMAN ALPHA FETOPROTEIN SPECIFIC T CELL RECEPTORS AND THEIR USES
US11635435B2 (en) 2017-06-13 2023-04-25 Oncotracker, Inc. Diagnostic, prognostic, and monitoring methods for solid tumor cancers
CA3076337A1 (en) 2017-09-19 2019-03-28 Massachusetts Institute Of Technology Compositions for chimeric antigen receptor t cell therapy and uses thereof
US12227554B2 (en) * 2017-10-05 2025-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for selectively expanding cells expressing a TCR with a murine constant region
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
WO2019075055A1 (en) 2017-10-11 2019-04-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS FOR PRODUCING T-CELL POPULATIONS USING P38 MAPK INHIBITORS
KR20190076297A (ko) 2017-12-22 2019-07-02 (주)메디톡스 Mart-1 특이적 t 세포 수용체 및 이의 용도
ES3052818T3 (en) 2018-02-09 2026-01-14 Us Health Tethered interleukin-15 and interleukin-21
SG11202009975TA (en) 2018-04-12 2020-11-27 Umoja Biopharma Inc Viral vectors and packaging cell lines
KR102892744B1 (ko) * 2018-04-19 2025-11-28 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Mage-b2 특이성을 갖는 t 세포 수용체 및 이의 용도
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
KR20210031898A (ko) * 2018-07-13 2021-03-23 난징 레전드 바이오테크 씨오., 엘티디. 전염병을 치료하기 위한 공동수용체 시스템
CN110818802B (zh) * 2018-08-08 2022-02-08 华夏英泰（北京）生物技术有限公司 一种嵌合t细胞受体star及其应用
EP4578507A3 (en) 2018-11-01 2025-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for t cell engineering
EP3884058A1 (en) 2018-11-21 2021-09-29 Umoja Biopharma, Inc. Multicistronic vector for surface engineering lentiviral particles
KR20200068263A (ko) 2018-12-05 2020-06-15 (주)메디톡스 Ny-eso-1 특이적 t 세포 수용체 및 이의 용도
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3924054B1 (en) 2019-02-15 2025-04-02 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020201527A1 (en) * 2019-04-04 2020-10-08 Umc Utrecht Holding B.V. Modified immune receptor constructs
JP2022538974A (ja) 2019-06-26 2022-09-07 マサチューセッツ インスチテュート オブ テクノロジー 免疫調節融合タンパク質－金属水酸化物錯体およびその方法
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
US20230057071A1 (en) 2019-12-20 2023-02-23 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
IL296242A (en) 2020-03-10 2022-11-01 Massachusetts Inst Technology Methods for generating engineered memory-like nk cells and compositions thereof
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
EP4168007A1 (en) 2020-06-23 2023-04-26 Novartis AG Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP4211228B1 (en) 2020-09-08 2025-11-05 The United States of America, as represented by the Secretary, Department of Health and Human Services T cell phenotypes associated with response to adoptive cell therapy
EP4243937A2 (en) 2020-11-13 2023-09-20 The United States of America, as represented by the Secretary, Department of Health and Human Services Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
CN116981357A (zh) 2021-03-31 2023-10-31 瑞泽恩制药公司 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
EP4370541A1 (en) 2021-07-14 2024-05-22 2seventy bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
WO2023002204A1 (en) * 2021-07-21 2023-01-26 Enara Bio Limited T-cell receptor
US20260083848A1 (en) 2021-11-03 2026-03-26 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
US20250057949A1 (en) 2021-12-31 2025-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic T cell therapy with vaccination as a combination immunotherapy against cancer
CN118475601A (zh) * 2022-01-05 2024-08-09 苏州系统医学研究所 一种t细胞受体及其制备方法和用途
AU2023248532A1 (en) 2022-04-08 2024-11-21 Regeneron Pharmaceuticals, Inc. Multipartite receptor and signaling complexes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE145428T1 (de) * 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US6407221B1 (en) * 1990-12-14 2002-06-18 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
WO2000056267A2 (en) * 1999-03-19 2000-09-28 Waldemar Priebe Methods and compositions for the manufacture of c-3' and c-4' anthracycline antibiotics
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances

Also Published As

Publication number Publication date
PT2016102E (pt) 2012-05-15
US20130116167A1 (en) 2013-05-09
US20090304657A1 (en) 2009-12-10
ES2382777T3 (es) 2012-06-13
WO2007131092A3 (en) 2008-04-03
AU2007248019B2 (en) 2012-10-11
AU2007248019A1 (en) 2007-11-15
WO2007131092A2 (en) 2007-11-15
EP2016102B1 (en) 2012-03-21
CA2651174A1 (en) 2007-11-15
ATE550356T1 (de) 2012-04-15
EP2016102A2 (en) 2009-01-21

Similar Documents

Publication Publication Date Title
PT2016102E (pt) Recetores de célula t quimérica e materiais relacionados e métodos de uso
Alto et al. Bioinformatic design of A-kinase anchoring protein-in silico: a potent and selective peptide antagonist of type II protein kinase A anchoring
NO20054116D0 (no) Trimerisk polypeptidkonstrukt for induksjon av vedvarende T-cellerespons
MX2009006892A (es) Uso de agonistas del receptor de peptido similar al glucagon de tipo 1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles de lipidos.
CO6390070A2 (es) Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas incluyendo receptor de factor de crecimiento tipo insulina -i
UA107921C2 (xx) Варіанти поліпептидів рецептора іів активіну та їх використання
AR064639A1 (es) Gen de bacillus thuringiensis con actividad contra lepidopteros
EP1994157A4 (en) RECOMBINANT HUMAN EPO-FC FUSION PROTEINS WITH LONGER HALF TIME AND INCREASED VIVO ERYTHROPOETIC ACTIVITY
MY177970A (en) Bcma (cd269/tnfrsf17) -binding proteins
BRPI0615657A2 (pt) seqüência de nucleotìdeos que codificam proteìnas inseticidas
EA200701362A1 (ru) Агонисты glp-1, композиции, способы и применения
AR078964A1 (es) Gen de bacillus thuringiensis que codifica polipeptido con actividad pesticida contra lepidoptera
DK1641818T3 (da) Polypeptider der har bindingsaffinitet for HER2
BRPI0508068A (pt) moléculas de ácido nucléico isoladas, vetor compreendendo as mesmas, polipeptìdeos isolados e composições compreendendo os mesmos
EA200601738A1 (ru) Модифицированные белки буганины, цитотоксины и способы их применения
DK1804835T3 (da) Multimere konstruktioner
Maqboul et al. Expression profiles of TRPV1, TRPV4, TLR4 and ERK1/2 in the dorsal root ganglionic neurons of a cancer-induced neuropathy rat model
ATE471336T1 (de) Das biomolekültransduktionsmotiv mph-1-btm und dessen verwendung
Hauck et al. Effects of synthesized elastin peptides on human leukocytes.
Moral‐Sanz et al. The structural conformation of the tachykinin domain drives the anti‐tumoural activity of an octopus peptide in melanoma BRAFV600E
WO2008109127A3 (en) New tumor mouse models using lentiviral vectors
AR070144A1 (es) Gen de bacillus thuringiensis con actividad contra coleopteros
BR122018077204B8 (pt) peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica
EP1807518A4 (en) RECOMBINANT ALPHA-FETOPROTEIN, METHOD AND MEANS FOR PREPARING THEREOF, COMPOSITIONS BASED THEREOF AND USE THEREOF
WO2003094841A3 (en) Mammalian genes involed in rapamycin resistance and tumorgenesis: annexin xiii genes